Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

Business Wire published this article on May 31, 2026. Insights found it while monitoring housing and property news for Ono, Japan. Only the headline and these details are shown here; the full article is on the publisher's site.

Publisher

Business Wire

Published

May 31, 2026

Market

Ono, Japan

Insights does not copy article text. Headlines belong to their publishers.